Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients.

Abstract

Background We undertook a randomised controlled trial to assess the efficacy and tolerability of orlistat, a gastrointestinal lipase inhibitor, in promoting weight loss and preventing weight regain in obese patients over a 2-year period. Methods 743 patients (body-mass index 28-47 kg/m2), recruited at 15 European centres, entered a 4-week, single-blind, placebo lead-in period on a slightly hypocaloric diet (600 kcal/day deficit). 688 patients who completed the lead-in were assigned double-blind treatment with orlistat 120 mg (three times a day) or placebo for 1 year in conjunction with the hypocaloric diet. In a second 52-week double-blind period patients were reassigned orlistat or placebo with a weight maintenance (eucaloric) diet. Findings From the start of lead-in to the end of year 1, the orlistat group lost, on average, more bodyweight than the placebo group (10.2% [10.3 kg] vs 6.1% [6.1 kg]; LSM difference 3.9 kg [p Interpretation Orlistat taken with an appropriate diet promotes clinically significant weight loss and reduces weight regain in obese patients over a 2-year period. The use of orlistat beyond 2 years needs careful monitoring with respect to efficacy and adverse events.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(97)11509-4

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 22 references

Research works printed but not linked: 1

  1. SIGN. Obesity in Scotland: integrating prevention with weight management. A National Clinical Guideline recommended for use in Scotland by the Scottish Intercollegiate Guidelines Network. Pilot edition, November, 1996.

Cited by

See all 1,237

Metadata

Authors
Sjöström, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H. P., & Krempf, M.
Affiliations
  • Sahlgrenska University Hospital (SE)
  • Helsinki University Hospital (FI)
  • Copenhagen University Hospital (DK)
  • University Hospital of Geneva (CH)
Corresponding author
Sjöström, Lars
Venue
The Lancet
Publisher
Elsevier BV
Published
1998-07
Volume
352
Issue
9123
Pages
167-172
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2134860420
Cited by
1,237
References
22
Citations by year
2026: 41 · 2025: 44 · 2024: 47 · 2023: 37 · 2022: 28 · 2021: 28 · 2020: 23 · 2019: 18 · 2018: 24 · 2017: 24 · 2016: 28 · 2015: 31 · 2014: 29 · 2013: 32 · 2012: 26
FWCI
43.96
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
Keywords
orlistat, obesity, weight loss, weight regain prevention, lipase inhibitors, hypocaloric diet, weight-maintenance diet, cholesterol, insulin, glucose, gastrointestinal adverse effects, long-term efficacy
MeSH terms
Orlistat, Adult, Blood Pressure, Energy Intake, Diet, Reducing, Double-Blind Method, Enzyme Inhibitors, Female, Follow-Up Studies, Humans, Lactones, Lipase, Lipids, Male, Middle Aged, Obesity, Risk Factors, Time Factors, Weight Loss, Body Mass Index, Single-Blind Method, Anti-Obesity Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. https://app.cochat.ai/papers/10.1016/s0140-6736(97)11509-4
The paper
Sjöström, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H. P., & Krempf, M. (1998). Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. The Lancet. https://doi.org/10.1016/s0140-6736(97)11509-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.